Literature DB >> 32234758

Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.

Alexandra O Sokolova1,2,3, Evan Y Yu1,2, Heather H Cheng4,2.   

Abstract

PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors.See related article by Abida et al., p. 2487. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32234758      PMCID： PMC7269828          DOI： 10.1158/1078-0432.CCR-20-0707

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.

Authors:  Ryan N Ptashkin; Diana L Mandelker; Catherine C Coombs; Kelly Bolton; Zarina Yelskaya; David M Hyman; David B Solit; José Baselga; Maria E Arcila; Marc Ladanyi; Liying Zhang; Ross L Levine; Michael F Berger; Ahmet Zehir
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

Review 2.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

Authors:  Clare L Scott; Elizabeth M Swisher; Scott H Kaufmann
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

Review 3.  Genetic Testing in Prostate Cancer.

Authors:  Alexandra O Sokolova; Heather H Cheng
Journal:  Curr Oncol Rep       Date:  2020-01-23       Impact factor: 5.075

4.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

Authors:  Wassim Abida; David Campbell; Akash Patnaik; Jeremy D Shapiro; Brieuc Sautois; Nicholas J Vogelzang; Eric G Voog; Alan H Bryce; Ray McDermott; Francesco Ricci; Julie Rowe; Jingsong Zhang; Josep Maria Piulats; Karim Fizazi; Axel S Merseburger; Celestia S Higano; Laurence E Krieger; Charles J Ryan; Felix Y Feng; Andrew D Simmons; Andrea Loehr; Darrin Despain; Melanie Dowson; Foad Green; Simon P Watkins; Tony Golsorkhi; Simon Chowdhury
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

5.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962
  5 in total
  2 in total

1.  Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.

Authors:  Alexandra O Sokolova; Catherine H Marshall; Rebeca Lozano; Roman Gulati; Elisa M Ledet; Navonil De Sarkar; Petros Grivas; Celestia S Higano; Bruce Montgomery; Peter S Nelson; David Olmos; Vadim Sokolov; Michael T Schweizer; Todd A Yezefski; Evan Y Yu; Channing J Paller; Oliver Sartor; Elena Castro; Emmanuel S Antonarakis; Heather H Cheng
Journal:  Prostate       Date:  2021-09-13       Impact factor: 4.104

Review 2.  Germline genetics of prostate cancer.

Authors:  Hiba M Khan; Heather H Cheng
Journal:  Prostate       Date:  2022-08       Impact factor: 4.012
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.